Cover Image
市場調查報告書

第二型糖尿病:全球臨床實驗檢討

Type 2 Diabetes Global Clinical Trials Review, H1, 2014

出版商 GlobalData 商品編碼 224001
出版日期 內容資訊 英文 319 Pages
訂單完成後即時交付
價格
Back to Top
第二型糖尿病:全球臨床實驗檢討 Type 2 Diabetes Global Clinical Trials Review, H1, 2014
出版日期: 2014年05月30日 內容資訊: 英文 319 Pages
簡介

本報告提供第二型糖尿病相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,及主要已開發國家·新興國家的臨床實驗狀況,地區、Phase、階段別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑等資訊,為您概述為以下內容。

目錄

簡介

  • 第二型糖尿病
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區的前五名國家
    • 歐洲的前五名國家
    • 北美的前幾名國家
    • 中東·非洲的前五名國家
    • 中南美的前五名國家

G7各國臨床實驗數量:代謝性疾病臨床實驗整體中,第二型糖尿病的比例

G7各國臨床實驗數量:Phase別

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:代謝性疾病臨床實驗整體中,第二型糖尿病的比例

E7各國臨床實驗數量:Phase別

E7各國臨床實驗數量:各進展狀況

Phase別臨床實驗數量

  • 進行中的臨床實驗:不同階段

各進展狀況臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

  • 參加第二型糖尿病治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Novo A/S
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Sanofi
    • Novartis AG
    • AstraZeneca PLC
    • GlaxoSmithKline plc
    • 武田藥品工業
    • Pfizer Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • Tehran University of Medical Sciences
    • 順天堂大學醫學系
    • Maastricht University Medical Center
    • U.S. Department of Veterans Affairs
    • Aarhus University
    • National Heart, Lung, and Blood Institute
    • Washington University School of Medicine
    • Vanderbilt University
    • Academic Medical Center

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC2185CTIDB

GlobalData's clinical trial report, "Type 2 Diabetes Global Clinical Trials Review, H1, 2014" provides data on the Type 2 Diabetes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Type 2 Diabetes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Type 2 Diabetes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Type 2 Diabetes
    • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
    • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
    • Top Five Countries Contributing to Clinical Trials in Europe
    • Top Countries Contributing to Clinical Trials in North America
    • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
    • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Type 2 Diabetes
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Type 2 Diabetes Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Type 2 Diabetes
      • May 15, 2014: Transition Therapeutics Diabetes Drug Candidate, TT-401, Commences Phase 2 Clinical Study
      • May 14, 2014: Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes
      • May 13, 2014: AstraZeneca announces positive results from Phase III study of saxagliptin/dapagliflozin combination in patients with type 2 diabetes inadequately controlled on metformin and outlines future development plans for the oral antidiabetic franchise
      • May 12, 2014: Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
      • May 12, 2014: Lilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes
      • May 01, 2014: Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
      • Apr 24, 2014: Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit
      • Apr 16, 2014: Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results for SGLT2 Inhibitor Remogliflozin Etabonate
      • Apr 09, 2014: Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
      • Apr 03, 2014: ProMetic's PBI-4050 Shown to Reduce Blood Glucose and Kidney Fibrosis in Preclinical Models of Human Type II Diabetes and Kidney Disease
      • Mar 30, 2014: Higher risks without cardio benefits halt study of aleglitazar
      • Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients
      • Mar 17, 2014: Theracos Reports Positive Outcomes from a 96-Week Phase 2 Study of THR1442, a Highly Specific SGLT2 Inhibitor, for the Treatment of Type 2 Diabetes
      • Mar 10, 2014: Fibrotech announces positive Phase Ia results for anti-fibrotic FT011
      • Mar 04, 2014: Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
      • Mar 04, 2014: Novo Nordisk Successfully Completes Phase I Trial of its Proprietary Oral Insulin using Merrion Pharmaceuticals' GIPET Technology.
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novo A/S
      • Clinical Trial Overview of Novo A/S
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Clinical Trial Overview of Top Institutes / Government
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases
      • Tehran University of Medical Sciences
      • Clinical Trial Overview of Tehran University of Medical Sciences
      • Juntendo University School of Medicine
      • Clinical Trial Overview of Juntendo University School of Medicine
      • Maastricht University Medical Center
      • Clinical Trial Overview of Maastricht University Medical Center
      • U.S. Department of Veterans Affairs
      • Clinical Trial Overview of U.S. Department of Veterans Affairs
      • Aarhus University
      • Clinical Trial Overview of Aarhus University
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Vanderbilt University
      • Clinical Trial Overview of Vanderbilt University
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Region, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Type 2 Diabetes Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Type 2 Diabetes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Type 2 Diabetes Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Type 2 Diabetes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Type 2 Diabetes Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Type 2 Diabetes Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Type 2 Diabetes Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Novo A/S, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Juntendo University School of Medicine, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Maastricht University Medical Center, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2014*

List of Figures

  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014*
  • Type 2 Diabetes Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Type 2 Diabetes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Type 2 Diabetes to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014*
  • Type 2 Diabetes Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Type 2 Diabetes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Type 2 Diabetes Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Type 2 Diabetes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top